Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) chief executive Ajan Reginald speaks to Thomas Warner from Proactive after the biotech company announced that it had achieved 'significant results' in laboratory studies involving its anti-cancer mRNA treatment.
Reginald reveals more information about the study and addresses the return of Roquefort shares to the market after a delayed audit prompted a temporary suspension.